IICT collaborated LAXAI Life Sciences to reduce dependency for APIs and drug intermediates

The initiative may help to reduce the dependency of the Indian pharmaceutical sector on Chinese imports of these ingredients.

Current Affairs:Indian Institute of Chemical Technology (IICT), Hyderabad, has collaborated with Hyderabad-based integrated pharmaceutical company, LAXAI Life Sciences, to develop and manufacture Active pharmaceutical ingredients (APIs) and drug intermediates. The initiative may help to reduce the dependency of the Indian pharmaceutical sector on Chinese imports of these ingredients. Coronavirus Cases

Provisions:
♦ The collaboration will use the know-how for the commercial manufacturing of the products. 
♦ LAXAI Life Sciences will be one of the first few to commercialize these products.  
♦ The manufacturing of these APIs and intermediates will be taken up at US Food and Drug Administration (USFDA)/Good manufacturing practice (GMP) approved plants held by LAXAI through its subsidiary, Therapiva Private Limited.

India’s dependency on APIs:
Active pharmaceutical ingredients (APIs) and intermediates are the key components of any drug that produces the intended effects. India is largely dependent especially on China for the supply of APIs and drug intermediates.

LAXAI Life Sciences Pvt. Ltd:
LAXAI Life Sciences Pvt. Ltd. was formed in 2007. The vision of the company is to accelerate the discovery chemistry campaign of global pharmaceutical companies. LAXAI is now an integrated pharmaceutical company with a presence in API/formulation development as well as API manufacturing. 

Leave a Reply

Your email address will not be published. Required fields are marked *